{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:58:48Z","timestamp":1792511928631,"version":"4.5.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018996","name":"Hellenic Academic Libraries Link","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijantimicag.2026.107784","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:46:43Z","timestamp":1773938803000},"page":"107784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prophylactic and therapeutic efficacy of monoclonal antibodies against avian influenza H5N1 virus"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2697-0654","authenticated-orcid":false,"given":"Antonios-Periklis","family":"Panagiotopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7666-9198","authenticated-orcid":false,"given":"Cleo","family":"Anastassopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2605-6956","authenticated-orcid":false,"given":"Kyriaki","family":"Ranellou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias","family":"Mariolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-4715","authenticated-orcid":false,"given":"Athanasios","family":"Tsakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2026.107784_bib0001","article-title":"Enhancing the response to avian influenza in the US and globally. The Lancet Regional Health","volume":"46","author":"Bartlett","year":"2025","journal-title":"Americas"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0002","article-title":"CDC A(H5N1) bird flu response update March 19, 2025","year":"2025","journal-title":"Avian Influenza (Bird Flu)"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2025.03.003","article-title":"Is a human highly pathogenic avian influenza A H5N1 pandemic inevitable?","author":"Gkrania-Klotsas","year":"2025","journal-title":"Clinical Microbiology and Infection"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0004","doi-asserted-by":"crossref","first-page":"e2243","DOI":"10.1002\/rmv.2243","article-title":"Influenza vaccines: past, present, and future","volume":"32","author":"Kim","year":"2022","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0005","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1038\/s41467-025-60714-4","article-title":"Increase in H5N1 vaccine antibodies confers cross-neutralization of highly pathogenic avian influenza H5N1","volume":"16","author":"Huang","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0006","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41586-025-09626-3","article-title":"A vaccine central in A(H5) influenza antigenic space confers broad immunity","volume":"647","author":"Kok","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0007","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0140-6736(23)00136-8","article-title":"Confronting the evolution and expansion of anti-vaccine activism in the USA in the COVID-19 era","volume":"401","author":"Carpiano","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105499","article-title":"Influenza antivirals and their role in pandemic preparedness","volume":"210","author":"Jones","year":"2023","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0009","article-title":"Antiviral strategies against H5N1: current options and emerging therapeutics","author":"Anastassopoulou","year":"2025","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0010","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0140-6736(24)01307-2","article-title":"Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials","volume":"404","author":"Gao","year":"2024","journal-title":"The Lancet"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0011","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.cmi.2025.04.002","article-title":"How to manage antivirals in critically ill patients with influenza?","volume":"31","author":"Bay","year":"2025","journal-title":"Clinical Microbiology and Infection"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0012","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s43556-024-00210-1","article-title":"Monoclonal antibodies: from magic bullet to precision weapon","volume":"5","author":"Aboul-Ella","year":"2024","journal-title":"Mol Biomed"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0013","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1016\/j.cell.2021.05.005","article-title":"Tackling COVID-19 with neutralizing monoclonal antibodies","volume":"184","author":"Corti","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0014","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","article-title":"Neutralizing monoclonal antibodies for treatment of COVID-19","volume":"21","author":"Taylor","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0015","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1854149","article-title":"Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline","volume":"12","author":"Tuccori","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105785","article-title":"Broadly neutralizing antibodies to combat influenza virus infection","volume":"221","author":"Sun","year":"2024","journal-title":"Antiviral Research"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0017","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1128\/jvi.67.5.2552-2558.1993","article-title":"A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains","volume":"67","author":"Okuno","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0018","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.antiviral.2010.09.007","article-title":"A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection","volume":"88","author":"Sakabe","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0019","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nsmb.1566","article-title":"Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses","volume":"16","author":"Sui","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0020","doi-asserted-by":"crossref","first-page":"e3942","DOI":"10.1371\/journal.pone.0003942","article-title":"Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from Human IgM+ memory B cells","volume":"3","author":"Throsby","year":"2008","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0021","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1126\/science.1171491","article-title":"Antibody recognition of a highly conserved influenza virus epitope","volume":"324","author":"Ekiert","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0022","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1086\/648378","article-title":"Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir","volume":"200","author":"Koudstaal","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0023","doi-asserted-by":"crossref","first-page":"e9106","DOI":"10.1371\/journal.pone.0009106","article-title":"New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets","volume":"5","author":"Friesen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0024","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.1222908","article-title":"Highly conserved protective epitopes on influenza B viruses","volume":"337","author":"Dreyfus","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183315","article-title":"Generation of a serum free CHO DG44 cell line stably producing a broadly protective anti-influenza virus monoclonal antibody","volume":"12","author":"Chromikova","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102618","article-title":"In silico structural homology modelling and docking for assessment of pandemic potential of a novel H7N9 influenza virus and its ability to be neutralized by existing anti-hemagglutinin antibodies","volume":"9","author":"Rajapaksha","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54934-3","article-title":"A single mutation in dairy cow-associated H5N1 viruses increases receptor binding breadth","volume":"15","author":"Good","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0028","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1038\/s41598-024-53049-5","article-title":"A pan-influenza monoclonal antibody neutralizes H5 strains and prophylactically protects through intranasal administration","volume":"14","author":"Beukenhorst","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0029","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-94314-5","article-title":"Intranasal administration of a panreactive influenza antibody reveals fc-independent mode of protection","volume":"15","author":"Beukenhorst","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41541-020-0206-5","article-title":"Adenovirus delivery of encoded monoclonal antibody protects against different types of influenza virus infection","volume":"5","author":"Wang","year":"2020","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0031","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0032","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006299","article-title":"Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza","volume":"5","author":"Limberis","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00865","article-title":"Therapeutic administration of broadly neutralizing FI6 antibody reveals lack of interaction between Human IgG1 and pig fc receptors","volume":"9","author":"Morgan","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0034","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","article-title":"Structure and function analysis of an antibody recognizing all influenza A subtypes","volume":"166","author":"Kallewaard","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0035","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/infdis\/jix292","article-title":"The hemagglutinin A stem antibody MEDI8852 prevents and controls disease and limits transmission of pandemic influenza viruses","volume":"216","author":"Paules","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0036","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1126\/science.ado6481","article-title":"Pre-exposure antibody prophylaxis protects macaques from severe influenza","volume":"387","author":"Kanekiyo","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0037","article-title":"A monoclonal anti-hemagglutinin stem antibody modified with zanamivir protects against both influenza A and B viruses","volume":"122","author":"Liu","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0038","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.str.2025.01.002","article-title":"Computational design and improvement of a broad influenza virus HA stem targeting antibody","volume":"33","author":"Duan","year":"2025","journal-title":"Structure"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0039","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00949-18","article-title":"Broadly reactive Human monoclonal antibodies elicited following pandemic H1N1 Influenza virus exposure protect mice against highly pathogenic H5N1 challenge","volume":"92","author":"Nachbagauer","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0040","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1172\/JCI41902","article-title":"Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine","volume":"120","author":"Corti","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0041","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ebiom.2017.03.007","article-title":"A broadly reactive human anti-hemagglutinin stem monoclonal antibody that inhibits influenza A virus particle release","volume":"17","author":"Yamayoshi","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0042","article-title":"Site-specific serology unveils cross-reactive monoclonal antibodies targeting influenza A hemagglutinin epitopes","volume":"54","author":"Paparoditis","year":"2024","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0043","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.AID-0021-2014","article-title":"Committing the oldest sins in the newest kind of ways-antibodies targeting the influenza virus type A hemagglutinin globular head","volume":"2","author":"Krause","year":"2014","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0044","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13152","article-title":"Neutralizing and protective murine monoclonal antibodies to the hemagglutinin of influenza H5 clades 2.3.2.1 and 2.3.4.4","volume":"17","author":"Schuele","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0045","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02065-16","article-title":"Divergent requirement of fc-fc\u03b3 receptor interactions for In vivo protection against influenza viruses by two pan-H5 hemagglutinin antibodies","volume":"91","author":"Wang","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0046","doi-asserted-by":"crossref","first-page":"8275","DOI":"10.1128\/JVI.02593-09","article-title":"An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses","volume":"84","author":"Oh","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0047","doi-asserted-by":"crossref","first-page":"12619","DOI":"10.1128\/JVI.01577-13","article-title":"A unique and conserved neutralization epitope in H5N1 influenza viruses identified by an antibody against the A\/Goose\/Guangdong\/1\/96 hemagglutinin","volume":"87","author":"Zhu","year":"2013","journal-title":"Journal of Virology"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0048","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.antiviral.2016.04.001","article-title":"Selection of therapeutic H5N1 monoclonal antibodies following IgVH repertoire analysis in mice","volume":"131","author":"Gray","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0049","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2035118","article-title":"The protective effect of a combination of human intracellular and extracellular antibodies against the highly pathogenic avian influenza H5N1 virus","volume":"18","author":"Jin","year":"2022","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0050","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1128\/JVI.00078-15","article-title":"An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection","volume":"89","author":"Zanin","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004192","article-title":"Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic Avian Influenza Virus infection","volume":"10","author":"Itoh","year":"2014","journal-title":"PLOS Pathogens"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0052","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2024.2302106","article-title":"Identification of specific neutralizing antibodies for highly pathogenic avian influenza H5 2.3.4.4b clades to facilitate vaccine design and therapeutics","volume":"13","author":"Tuan Duong","year":"2024","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0053","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1038\/s41467-022-32926-5","article-title":"Identification of a cross-neutralizing antibody that targets the receptor binding site of H1N1 and H5N1 influenza viruses","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0054","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.cell.2019.04.011","article-title":"A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface","volume":"177","author":"Bangaru","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0055","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/infdis\/jiae379","article-title":"An update on highly pathogenic Avian Influenza A(H5N1) virus, clade 2.3.4.4b","volume":"230","author":"Webby","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.786617","article-title":"Influenza neuraminidase characteristics and potential as a vaccine target","volume":"12","author":"Creytens","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0057","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00332-22","article-title":"Novel epitopes of the Influenza Virus N1 neuraminidase targeted by Human monoclonal antibodies","volume":"96","author":"Kirkpatrick Roubidoux","year":"2022","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0058","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/v15010200","article-title":"Broadly protective neuraminidase-based influenza vaccines and monoclonal antibodies: target epitopes and mechanisms of action","volume":"15","author":"Abbadi","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0059","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.immuni.2024.02.003","article-title":"Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase","volume":"57","author":"Lederhofer","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0060","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cell.2018.03.030","article-title":"Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies","volume":"173","author":"Chen","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0061","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.immuni.2023.07.004","article-title":"Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo","volume":"56","author":"Hansen","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0062","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.chom.2024.12.004","article-title":"Identification of a broad-inhibition influenza neuraminidase antibody from pre-existing memory B cells","volume":"33","author":"Wang","year":"2025","journal-title":"Cell Host & Microbe"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0063","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.1038\/s41467-022-34521-0","article-title":"A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases","volume":"13","author":"Yasuhara","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0064","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01584-17","article-title":"Antibodies directed toward neuraminidase N1 control disease in a mouse model of influenza","volume":"92","author":"Job","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0065","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.1038\/s41467-025-62174-2","article-title":"Structural basis of broad protection against influenza virus by human antibodies targeting the neuraminidase active site via a recurring motif in CDR H3","volume":"16","author":"Jo","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0066","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01027-20","article-title":"Matrix protein 2 extracellular domain-specific monoclonal antibodies are an effective and potentially universal treatment for Influenza A","volume":"95","author":"Bimler","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0067","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.1073\/pnas.0911806107","article-title":"Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses","volume":"107","author":"Grandea","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0068","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1099\/jgv.0.000518","article-title":"Cross-protective potential of anti-nucleoprotein human monoclonal antibodies against lethal influenza A virus infection","volume":"97","author":"Fujimoto","year":"2016","journal-title":"J Gen Virol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0069","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a038638","article-title":"Hemagglutinin structure and activities","volume":"11","author":"Gamblin","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0070","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/antib14010004","article-title":"How broadly neutralising antibodies are redefining immunity to influenza","volume":"14","author":"Steventon","year":"2025","journal-title":"Antibodies"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0071","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28706-1","article-title":"The influenza virus hemagglutinin head evolves faster than the stalk domain","volume":"8","author":"Kirkpatrick","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0072","doi-asserted-by":"crossref","first-page":"e4260","DOI":"10.1093\/cid\/ciaa1725","article-title":"Safety and efficacy of CR6261 in an influenza A H1N1 healthy human challenge model","volume":"73","author":"Han","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0073","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.biologicals.2017.08.007","article-title":"A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers","volume":"50","author":"Mallory","year":"2017","journal-title":"Biologicals"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0074","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00694-18","article-title":"Evaluation of MEDI8852, an anti-influenza A monoclonal antibody, in treating acute uncomplicated influenza","volume":"62","author":"Ali","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0075","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1128\/AAC.00607-16","article-title":"Two phase 1, randomized, double-blind, placebo-controlled, single-ascending-dose studies to investigate the safety, tolerability, and pharmacokinetics of an Anti-Influenza A virus monoclonal antibody, MHAA4549A, in healthy volunteers","volume":"60","author":"Lim","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0076","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01154-17","article-title":"Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A virus challenge model","volume":"61","author":"McBride","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0077","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40262-017-0564-y","article-title":"Pharmacokinetics of MHAA4549A, an Anti-Influenza A monoclonal antibody, in healthy subjects challenged with Influenza A virus in a phase IIa randomized trial","volume":"57","author":"Deng","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0078","doi-asserted-by":"crossref","first-page":"ofab630","DOI":"10.1093\/ofid\/ofab630","article-title":"A phase 2 randomized, double-blind, placebo-controlled trial of the monoclonal antibody MHAA4549A in patients with acute uncomplicated influenza A infection","volume":"9","author":"Lim","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0079","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00352-20","article-title":"A phase 2 randomized, double-blind, placebo-controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir in patients hospitalized with severe influenza A virus infection","volume":"64","author":"Lim","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0080","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/infdis\/jiu539","article-title":"Efficacy and safety of treatment with an anti-M2e monoclonal antibody in experimental Human influenza","volume":"211","author":"Ramos","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0081","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01273-23","article-title":"A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness","volume":"68","author":"Plotnik","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0082","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/cid\/ciae368","article-title":"A randomized, placebo-controlled trial to evaluate the safety and efficacy of VIR-2482 in healthy adults for prevention of influenza A illness (PENINSULA)","volume":"79","author":"Tan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0083","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ebiom.2016.02.021","article-title":"Safety and upper Respiratory pharmacokinetics of the hemagglutinin stalk-binding antibody VIS410 support treatment and prophylaxis based on population modeling of seasonal Influenza A outbreaks","volume":"5","author":"Wollacott","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104763","article-title":"Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study","volume":"184","author":"Sloan","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0085","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ebiom.2018.12.051","article-title":"Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: results from a randomized, double-blind, phase-2, placebo-controlled study","volume":"40","author":"Hershberger","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0086","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1093\/infdis\/jiaf216","article-title":"Polyclonal and monoclonal antibodies for the treatment and prevention of influenza","volume":"232","author":"Beigel","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0087","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236172","article-title":"Broader neutralization of CT-P27 against influenza A subtypes by combining two human monoclonal antibodies","volume":"15","author":"Yi","year":"2020","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0088","unstructured":"Clinicaltrials.Gov. NCT03511066 https:\/\/clinicaltrials.gov\/study\/NCT03511066 (accessed 08 December 2025)"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0089","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/19420862.2016.1167294","article-title":"Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A","volume":"8","author":"Gupta","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0090","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/jcph.1652","article-title":"Pharmacokinetics of the monoclonal antibody MHAA4549A administered in combination with Oseltamivir in patients hospitalized with severe influenza A infection","volume":"60","author":"Deng","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0091","doi-asserted-by":"crossref","first-page":"10890","DOI":"10.1073\/pnas.1502374112","article-title":"A broadly neutralizing human monoclonal antibody is effective against H7N9","volume":"112","author":"Tharakaraman","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0092","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.02457-15","article-title":"The hemagglutinin stem-binding monoclonal antibody VIS410 controls Influenza virus-induced acute Respiratory distress syndrome","volume":"60","author":"Baranovich","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0093","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.immuni.2025.02.006","article-title":"Antigenic drift expands influenza viral escape pathways from recalled humoral immunity","volume":"58","author":"Maurer","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0094","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2022.2155072","article-title":"Alarming situation of emerging H5 and H7 avian influenza and effective control strategies","volume":"12","author":"Shi","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0095","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.molimm.2013.07.010","article-title":"The antigenic architecture of the hemagglutinin of influenza H5N1 viruses","volume":"56","author":"Velkov","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0096","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105632","article-title":"Large-scale computational modelling of H5 influenza variants against HA1-neutralising antibodies","volume":"114","author":"Ford","year":"2025","journal-title":"eBioMedicine"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0097","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.70012","article-title":"Molecular evolution of the H5 and H7 highly pathogenic avian influenza virus haemagglutinin cleavage site motif","volume":"35","author":"Luczo","year":"2025","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0098","doi-asserted-by":"crossref","first-page":"fuae014","DOI":"10.1093\/femsre\/fuae014","article-title":"Epitopes in the HA and NA of H5 and H7 avian influenza viruses that are important for antigenic drift","volume":"48","author":"Luczo","year":"2024","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0099","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.it.2023.11.001","article-title":"Targeting neuraminidase: the next frontier for broadly protective influenza vaccines","volume":"45","author":"Wu","year":"2024","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40259-023-00641-2","article-title":"Reducing immunogenicity by design: approaches to minimize immunogenicity of monoclonal antibodies","volume":"38","author":"Harris","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0101","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/vaccines12060566","article-title":"Vaccines for the elderly and Vaccination Programs in Europe and the United States","volume":"12","author":"Anastassopoulou","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0102","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: an immunologic perspective","volume":"8","author":"Rosenberg","year":"2006","journal-title":"AAPS J"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0103","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/08916930601165180","article-title":"Altered immunogenicity of isoaspartate containing proteins","volume":"40","author":"Doyle","year":"2007","journal-title":"Autoimmunity"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0104","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.cmi.2024.01.025","article-title":"Which trial do we need? Randomized, placebo-controlled trial of antiviral treatment in patients hospitalized for influenza","volume":"30","author":"Hosszu-Fellous","year":"2024","journal-title":"Clinical Microbiology and Infection"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0105","unstructured":"CDC. Influenza: developing drugs for treatment and\/or prophylaxis. 2011; https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/influenza-developing-drugs-treatment-andor-prophylaxis (accessed 22 October 2025)."},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0106","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1669073","article-title":"Monoclonal antibodies against influenza viruses: a clinical trials review","volume":"16","author":"Mota","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0107","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00052-20","article-title":"Airway delivery of anti-influenza monoclonal antibodies results in enhanced antiviral activities and enables broad-coverage combination therapies","volume":"94","author":"Vigil","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0108","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3390\/jpm12030439","article-title":"The role of oral antivirals for COVID-19 treatment in shaping the pandemic landscape","volume":"12","author":"Anastassopoulou","year":"2022","journal-title":"J Personalized Med"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0109","article-title":"Physical Instabilities of therapeutic monoclonal antibodies: a critical review","volume":"19","author":"Bana","year":"2022","journal-title":"Curr Drug Discov Technol"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0110","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2451789","article-title":"Cost and supply considerations for antibody therapeutics","volume":"17","author":"Chen","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.ijantimicag.2026.107784_bib0111","first-page":"109","article-title":"Pricing of monoclonal antibody therapies: higher if used for cancer?","volume":"24","author":"Hernandez","year":"2018","journal-title":"Am J Manag Care"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926000737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926000737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T19:03:20Z","timestamp":1779735800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926000737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":111,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0924857926000737"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107784","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylactic and therapeutic efficacy of monoclonal antibodies against avian influenza H5N1 virus","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107784"}}